Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy.

Trial Profile

Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs CDX-3379 (Primary) ; Cetuximab; Erlotinib; Trastuzumab; Vemurafenib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics; Kolltan Pharmaceuticals
  • Most Recent Events

    • 21 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 06 Apr 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 06 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 28 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top